Articles related to ANTI-PSYCHOTICS

Among the approved SGAs for MDD, no single medication stands out as the first choice; decision-making is guided by individual patient profiles and side effect considerations.

Metformin is emerging as a viable option for weight management in obese patients without diabetes, showing sustained weight loss effects and potential benefits in populations with prediabetes or undergoing antipsychotic treatment.

The Johns Hopkins Clozapine Consultation Clinic is addressing the critical underutilization of clozapine in treatment-resistant schizophrenia, providing essential support and education for healthcare providers in navigating its benefits and risks.

LYN-005 represents a breakthrough in schizophrenia management, showing promise in maintaining therapeutic levels and symptom control with just once-weekly dosing.

The JEWEL study has demonstrated that lurasidone treatment in patients with schizophrenia results in significant improvements in social functioning, with notable progress observed from the early stages of treatment and sustained benefits over a 12-week extension period.

In a phase 3 study, iloperidone demonstrated a significant improvement in treating bipolar mania, marked by a reduction in the Young Mania Rating Scale (YMRS) scores.